Anticancer agent 25
Anticancer agent 25 is an anticancer agent. Anticancer agent 25 can arrest the cell cycle at the G1 phase, and significantly inhibit tumor cell colony forming and migration even at low concentrations. Anticancer agent 25 can significantly induce cytoplasmic vacuolation. Anticancer agent 25 can be used for the study of prostate cancer, breast cancer, and colon cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2401013-08-7
- 分子式: C37H45BrN2O3
- 分子量:645.67
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
|
Cell Cycle/DNA Damage 0.19 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
0.74 μM
Compound: 18e
|
Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 31812467] |
| HCT-116 | IC50 |
0.55 μM
Compound: 18e
|
Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 31812467] |
| HT-29 | IC50 |
0.56 μM
Compound: 18e
|
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 31812467] |
| MDA-MB-231 | IC50 |
1.31 μM
Compound: 18e
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 31812467] |
| PC-3 | IC50 |
0.19 μM
Compound: 18e
|
Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human PC3 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 31812467] |
体外実験
Anticancer agent 25 (Compound 18e) shows antiproliferative activity against prostate cancer cell lines, PC3 (IC50 = 0.19 μM) and DU145 (IC50 = 0.74 μM); breast cancer cell line MDA-MB-231 (IC50 = 1.31 μM); and human colon cancer cell lines, HT29 (IC50 = 0.56 μM) and HCT116 (IC50 = 0.55 μM); and exhibits low toxicity against normal human aortic fibroblasts (HAF) (IC50 = 3.95 μM)[1].
Anticancer agent 25 (0.5-2 μM, 24 h) induces G1 phase arrest in PC3 cells in a dose-dependent manner[1].
Anticancer agent 25 (0.1-2 μM, 24 h) can significantly inhibit the long-term proliferation ability of PC3 tumor cells even at extremely low concentrations[1].
Anticancer agent 25 (0.1-2 μM, 24 h) significantly and in a dose-dependent manner inhibits the migration ability of PC3 cells[1].
Anticancer agent 25 (0.5-1 μM, 24 h) can induce significant cytoplasmic vacuolation in PC3 cells even at low concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC3 cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:24 h
-
Result:Caused ~ 50% inhibition on the colony forming at 0.1 μM and ~ 90% inhibition at 0.5 μM.
化学情報
-
CAS 番号 2401013-08-7
-
分子量 645.67
-
分子式 C37H45BrN2O3
-
SMILES
CC(C)C(C=C1)=CC=C1CC2=C3C=CC(OC)=C(NCCCCCCCC)C3=C[N+]4=C2C5=CC6=C(C=C5CC4)OCO6.[Br-]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)